Safety and Tolerability of High-dose Inhaled Treprostinil in Pulmonary Hypertension
| Autor: | Abby Poms, Victor F. Tapson, Terry Fortin, Kishan S. Parikh, Sudarshan Rajagopal |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
Hypertension Pulmonary 030204 cardiovascular system & hematology Article Cohort Studies 03 medical and health sciences 0302 clinical medicine Interquartile range Administration Inhalation Humans Medicine Familial Primary Pulmonary Hypertension Antihypertensive Agents Retrospective Studies Pharmacology Throat irritation Dose-Response Relationship Drug Inhalation Maintenance dose business.industry Retrospective cohort study Middle Aged medicine.disease Epoprostenol Pulmonary hypertension Treatment Outcome 030228 respiratory system Tolerability Anesthesia Female medicine.symptom Cardiology and Cardiovascular Medicine business Follow-Up Studies Treprostinil medicine.drug |
| Zdroj: | Journal of Cardiovascular Pharmacology. 67:322-325 |
| ISSN: | 0160-2446 |
| Popis: | Pulmonary arterial hypertension (PAH) has emerging therapeutic options including prostacyclin analogs. Inhaled therapy offers advantages compared with alternative routes of administration. We aimed to determine the safety and tolerability of inhaled treprostinil (iTRE) titrated to target maintenance dose higher than the labeled dose for PAH. Our study included 80 consecutive patients (69% female, 70% White) followed at the Duke University Medical Center prescribed iTRE at dose >9 breaths (54 μg). Etiology of pulmonary hypertension was most frequently PAH (51%) or secondary to lung disease (35%). Median follow-up was 20.3 months (interquartile range 14.2-33.2). Most patients (91%) had titrated iTRE dose to 12 breaths (72 μg) four times daily. Common side effects reported with drug initiation were cough (41%), headache (28%), and throat irritation (8%); most of the side effects improved at follow-up. Overall, 25% patients discontinued iTRE: 9 transitioned to parenteral therapy, 4 had untolerable side effects, 3 died, and 4 had other reasons. Overall, iTRE taken at a higher dose than approved for use in PAH was safe and well-tolerated in our cohort of pulmonary hypertension patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|